Translation cellular immunotherapy of idiopathic and immunosuppressive Kaposi's sarcoma

M. G Kartashova; A. V Kildyushevsky; A. V Molochkov; V. A Fedulkina

doi:10.17816/dv36758

Russian Journal of Skin and Venereal Diseases ›› 2013, Vol. 16 ›› Issue (3) : 13 -18. DOI: 10.17816/dv36758

Articles

research-article

Translation cellular immunotherapy of idiopathic and immunosuppressive Kaposi's sarcoma

Author information +

History +

PDF

Abstract

Translation cellular immunotherapy with ammifurine photosensitizer and UV irradiation (spectrum A) of cellular mononuclear suspension (λ = 320-340 nm, 90 min), followed by its reinfusion, were carried out in 20 patients with Kaposi’s sarcoma (15 with the idiotypical and 5 with immunosuppressive type) aged 32-75 years. Evaluation of the immune status of patients, including phenotyping, was carried out before and after therapy and demonstrated the treatment efficiency, shown by the time course of the clinical picture and periods of disease remission. The treatment efficiency is explained by induction of antitumor immunological surveillance. Relevant publications (8 references) are discussed.

Keywords

Kaposi’s sarcoma / translation cellular immunotherapy / dendritic cells

Cite this article

Download citation ▾

M. G Kartashova, A. V Kildyushevsky, A. V Molochkov, V. A Fedulkina. Translation cellular immunotherapy of idiopathic and immunosuppressive Kaposi's sarcoma. Russian Journal of Skin and Venereal Diseases, 2013, 16(3): 13-18 DOI:10.17816/dv36758

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Молочков А.В., Казанцева И.А., Гурцевич В. Э. Саркома Капоши. М.: БИНОМ; 2000.

[2]	Moore P.S., Gao S.J., Dominguez G., Cesarman E., Lungu O., Knowles D.M., et al. Primary characterization of a herpesvirus agent associated with Kaposi’s sarcoma. J. Virol. 1996; 70(1): 549-58.

[3]	Renne R., Zhong W., Herndier B., McGrath M., Abbey N., Kedes D., Ganem D. Lytic growth of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat. Med. 1996; 2(3): 342-6.

[4]	Luger T.A., Schwarz T., Krutmann J., Kock A., Urbanski A., Kirnbauer R. Cytokinesand theskin. Curr. Probl. Dermatol. 1990; 19: 35-49.

[5]	Кильдюшевский А.В., Молочков В А., Ольшанский А.Я., Молочков А.В., Фомин А.М., Гордиевская М.С. и др. Способ лечения Т-клеточных лимфом и саркомы Капоши. Патент № 2401671 от 20.10.2010. Изобретения и полезные модели. 2010; 29.

[6]	Timmerman J.M., Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 1999; 50: 507-29.

[7]	Aichele P., Brduscha-Riem K., Zinkernagel R.M., Hengartner H., Pircher H. T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 1995; 182(1): 261-6.

[8]	Marincola F.M., Jaffee E.M., Hicklin D.J., Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 2000; 74: 181-273.